April Sena

Company: Life Edit Therapeutics

Job title: Vice President, Technical Operations

Seminars:

Novel Approach to Treating Rare Disease Using an AAV Vector to Deliver Gene Editing Tools to the Brain 2:00 pm

Provide overview of the development of LETI-101, a preclinical stage AAV5-delivered Life Edit® nuclease and guide RNA for mutant allele-specific editing in Huntington’s Disease Share approach for assessing manufacturability of LETI-101 through linking preclinical and CMC efforts Discuss the importance of biotech “owning” the future CMC problems at an early stage of pharmaceutical development to…Read more

day: Conference Day Two